An observational study in Aortic Stenosis Disease, sponsored by Vastra Gotaland Region. Recruiting at 2 sites in Sweden. Per ClinicalTrials.gov, last updated 2026-06-02.
Sponsored by Vastra Gotaland Region · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Aortic Valve Stenosis with a site in Sweden — 11 open to participants now, 17 under way, none of them phase 3. Aortic Valve Stenosis · Sweden.
Among the 38 studies in Aortic Valve Stenosis with a site in Sweden, this one is the 10th largest by planned enrollment of the 19 observational ones that give a count, is one of 3 that started in 2025, is one of 19 observational ones, reaches primary completion later than 16 of the 16 other live ones, and was the 35th registered.
1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.
Browse Aortic Valve Stenosis studies →11 of the 38 studies in Aortic Valve Stenosis with a site in Sweden are open now. Recruiting first, the newest first:
Copenhagen University Hospital, Rigshospitalet · Sites in Sweden, Denmark
Ages 18+
Ole De Backer · Sites in Sweden, Belgium, Denmark and 3 more countries
Ages 18+
Vastra Gotaland Region · Sites in Sweden
Ages 65+
Abbott Medical Devices · Sites in Sweden, Australia, France and 8 more countries
Ages 18–100
Queen Silvia Children's Hospital, Gothenburg, Sweden · Sites in Sweden, United States, Austria and 5 more countries
Ages 23 wk–31 wk
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 200 across 437 observational studies indexed under Aortic Valve Stenosis.
Median enrollment 135 across the 19 interventional studies, 300 across the 19 observational. Of the 19 that completed or were terminated, 4 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 38 have an industry lead sponsor. The 10 most frequent:
Vastra Gotaland Region is the lead sponsor of 276 studies on the registry; 110 are open to participants now.
Vastra Gotaland Region has 2 studies filed under Aortic Valve Stenosis — fewer than ten, so there is no comparison to draw.
2 of the studies in Aortic Valve Stenosis with a site in Sweden that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05932615Abbott Medical DevicesENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2027-04 |
| NCT06008080Abbott Medical DevicesPost-Market Clinical Follow Up Study With Navitor Valve | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 38 studies in Aortic Valve Stenosis with a site in Sweden, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The investigators will prospectively enroll 300 patients undergoing TAVI at Sahlgrenska University Hospital, which is the second largest TAVI hospital in Sweden. Eligible patients should have a clinical indication for aortic valve replacement with TAVI and have preprocedural clinical investigations with echocardiography (UCG) and CCT and provide written informed consent. UCG, electrocardiogram (ECG) and blood samples will be taken in addition to clinical status, NYHA-class and collection of outcome events the day before the procedure, 1±2 hours, 24 ±6hours and daily after the procedure until discharged from Sahlgrenska. Further follow-up will be scheduled day 14, 30, 180, 365 and yearly. Cardiac MRI will be performed before, at 14 days and at 180 days after TAVI. Brain MRI will be performed before and 24± hours after TAVI. Cardiac CT will be performed at 180 days after TAVI.
CMR and Brain MRI poses no increased risk of causing serious adverse events for patients participating in the study. However, patients with clear contraindication will not be included to the study. (e.g. patients with MRI non-compatible metal device present in body, claustrophobia or for other reasons set at the local clinic). Patients with kidney failure (estimated glomerular filtration rate \<30 ml/kg/min,) will not be given MRI contrast medium.
MRI is planned before the TAVI procedure (baseline), 24 hours (Brain MRI) and at 180 days (CMR) after TAVI.
We will prospectively enroll 300 patients undergoing TAVI at Sahlgrenska University Hospital
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
300 patients undergoing TAVI at Sahlgrenska University Hospital
Cardiac damage
To study change in stage of cardiac damage (stage 0-4) by echocardiography.
Time frame: Baseline and 180 days
Change in echocardiography parameters
To study E/é ratio in echocardiography derived parameters indicating cardiac damage (delta%)
Time frame: Baseline and at 14, 30 and 180 days
Change in echocardiography parameters
To study Left ventricular mass change on echocardiography (delta gram)
Time frame: Baseline and at 14, 30 and 180 days
Left Atrial -strain
To study change in LA-strain derived by echocardiography (delta %)
Time frame: Baseline and at 14, 30 and 180 days
Change in echocardiography parameters
To study the influence of effectiv orfice area (cm2)of the aortic valve on cardiac damage (stage 0-4)
Time frame: Baseline and at 14, 30 and 180 days
Cardiac Magnetic Resonance (CMR)
Change in CMR derived parameters Left ventricular mass (delta gram)
Time frame: Baseline and at 14 and 180 days
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2025 (actual). Primary completion is estimated for Dec 2030, 69 months after the start.
Of 206 non-industry observational studies under Aortic Valve Stenosis, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 120. This study's planned 69 months is above that.
Counting every sponsor, half of 243 studies reached it within 44 months; a quarter within 23 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.